-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。ペンスキー・オートモーティブ（PAG）は、第1四半期の調整後EPSが3.05ドル（前年同期比15%減）となり、市場予想の2.88ドルを上回りました。この好調は、売上高が予想を上回ったことが要因です。売上高は1.1%減の78億6,000万ドル（市場予想を1億5,000万ドル上回る）、粗利益率は10ベーシスポイント低下の16.5%（市場予想を10ベーシスポイント下回る）となりました。売上高の減少は販売台数の減少によるもので、販売台数は2.8%減の12万3,173台でした。特筆すべきは、為替変動が売上高に約2億2,800万ドルの追い風となり、特に英国（総売上高の約30%）におけるPAGの国際的な事業展開が恩恵を受けたことです。 PAGは第1四半期に2,640万ドルで17万株を自社株買いしました（発行済み株式総数の約1.8%）。経営陣はまた、2月に年間4億5,000万ドルの収益増が見込まれるディーラーの買収を完了しました。自動車ディーラー業界にとって厳しい状況にもかかわらず、PAGの収益が予想を上回ったことから、これは堅調な発表だったと私たちは考えています。株価はプレマーケット取引で3%上昇しました。他の主要な米国拠点の自動車ディーラーと比較して、PAGの米国以外の事業比率が高いことが、業績向上に貢献しました。
Related Articles
Research
Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.
$ESS
Research
Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.
$BIIB
Australia
Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says
Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%
$SBUX